{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T20:11:35Z","timestamp":1787083895025,"version":"build-2736575974"},"reference-count":153,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Androgen deprivation therapy (ADT) is a mainstay treatment for metastatic prostate cancer, improving progression-free survival. ADT suppresses the production of testosterone and reduces circulating levels of the hormone. Luteinizing hormone-releasing hormone (LH-RH) agonists are the most commonly used ADT modality. They can be given alone or in combination with androgen synthesis inhibitors or androgen receptor antagonists. An estimated 40% of prostate cancer patients will receive ADT as part of their therapy during their lifetime. However, ADT has numerous adverse effects, including an increased cardiovascular risk that impacts quality of life. Relugolix is an alternative form of ADT. It is the only oral gonadotropin-releasing hormone antagonist, circumventing injection site reactions, making it easier for patients to take, and thus increasing compliance. Testosterone suppression with relugolix is excellent and testosterone recovery after discontinuation is rapid. This paper reviews the ADT and anti-androgen treatment options for men with prostate cancer and the cardiovascular effects of these therapies. There is accumulating evidence that cardiovascular risk with relugolix is lower than with other ADT medications and also lower than with androgen synthesis inhibitors and androgen receptor antagonists. This paper provides insight into the use of different ADT regimens based on the cardiovascular status and circumstances. It explores strategies to mitigate negative cardiovascular consequences and highlights the need for further study.<\/jats:p>","DOI":"10.3390\/medicina60111727","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T06:11:25Z","timestamp":1729577485000},"page":"1727","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer"],"prefix":"10.3390","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4478-2441","authenticated-orcid":false,"given":"Allison B.","family":"Reiss","sequence":"first","affiliation":[{"name":"Department of Medicine and Foundations of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Vasalani","sequence":"additional","affiliation":[{"name":"Department of Medicine and Foundations of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2549-214X","authenticated-orcid":false,"given":"Jacqueline","family":"Albert","sequence":"additional","affiliation":[{"name":"Department of Medicine and Foundations of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Drewes","sequence":"additional","affiliation":[{"name":"Department of Medicine and Foundations of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Department of Medicine and Foundations of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"De Leon","sequence":"additional","affiliation":[{"name":"Department of Medicine and Foundations of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron E.","family":"Katz","sequence":"additional","affiliation":[{"name":"Department of Urology, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Wang, L., Lu, B., He, M., Wang, Y., Wang, Z., and Du, L. (2022). Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries from 2000 to 2019. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.811044"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1016\/j.scib.2023.09.041","article-title":"Global, regional, and national lifetime probabilities of developing cancer in 2020","volume":"68","author":"Zheng","year":"2023","journal-title":"Sci. Bull."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.15585\/mmwr.mm6941a1","article-title":"Prostate Cancer Incidence and Survival, by Stage and Race\/Ethnicity-United States, 2001\u20132017","volume":"69","author":"Siegel","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_5","unstructured":"Centers for Disease Control and Prevention (2024, September 09). \u201cU.S. Cancer Statistics Prostate Cancer Stat Bite\u201d. U.S. Department of Health and Human Services, Available online: https:\/\/www.cdc.gov\/united-states-cancer-statistics\/publications\/prostate-cancer-stat-bite.html."},{"key":"ref_6","unstructured":"(2024, September 26). American Cancer Society Survival Rates for Prostate Cancer. Available online: https:\/\/www.cancer.org\/cancer\/types\/prostate-cancer\/detection-diagnosis-staging\/survival-rates.html."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ho, A.Y., Li, E.V., Bennett, R., Suk-Ouichai, C., Kumar, S.K.S.R., Neill, C., Li, Y., Schaeffer, E.M., Morgans, A.K., and Patel, H.D. (2024). Testosterone recovery after androgen deprivation therapy. Urol. Oncol., in press.","DOI":"10.1016\/j.urolonc.2024.08.005"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e000040","DOI":"10.1136\/esmoopen-2016-000040","article-title":"International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries","volume":"1","author":"Liede","year":"2016","journal-title":"ESMO Open"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.urolonc.2009.09.004","article-title":"Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States","volume":"29","author":"Gilbert","year":"2011","journal-title":"Urol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e433126","DOI":"10.1200\/EDBK_433126","article-title":"Balancing Hormone Therapy: Mitigating Adverse Effects of Androgen-Deprivation Therapy and Exploring Alternatives in Prostate Cancer Management","volume":"44","author":"Gudenkauf","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1159\/000513258","article-title":"Localized and Locally Advanced Prostate Cancer: Treatment Options","volume":"99","author":"Achard","year":"2021","journal-title":"Oncology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11523-023-00967-5","article-title":"A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer","volume":"18","author":"Dunshee","year":"2023","journal-title":"Target. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11523-022-00944-4","article-title":"Relugolix: A Review in Advanced Prostate Cancer","volume":"18","author":"Shirley","year":"2023","journal-title":"Target. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.2147\/DDDT.S373546","article-title":"Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy","volume":"17","author":"Tatenuma","year":"2023","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/14656566.2022.2033210","article-title":"Advances with androgen deprivation therapy for prostate cancer","volume":"23","author":"Yu","year":"2022","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/CCO.0000000000000723","article-title":"Highlighting recent treatment advances in metastatic prostate cancer: Expanding the treatment arsenal","volume":"33","author":"Gourdin","year":"2021","journal-title":"Curr. Opin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e2119568","DOI":"10.1001\/jamanetworkopen.2021.19568","article-title":"Causes of Death among Patients with Metastatic Prostate Cancer in the US from 2000 to 2016","volume":"4","author":"Elmehrath","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e2120889","DOI":"10.1001\/jamanetworkopen.2021.20889","article-title":"Exploring the causes of death among patients with metastatic prostate cancer\u2014A changing landscape","volume":"4","author":"Merriel","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1002\/cncr.33486","article-title":"Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the prostate lung, colorectal and ovarian (PLCO0 randomized control trial","volume":"127","author":"Butler","year":"2021","journal-title":"Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jaccao.2020.08.011","article-title":"Reduced Cardiorespiratory Fitness and Increased Cardiovascular Mortality After Prolonged Androgen Deprivation Therapy for Prostate Cancer","volume":"2","author":"Gong","year":"2020","journal-title":"JACC CardioOncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1016\/j.clgc.2022.12.006","article-title":"Association of Androgen Deprivation Therapy with Metabolic Disease in Prostate Cancer Patients: An Updated Meta-Analysis","volume":"21","author":"Swaby","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.109.192695","article-title":"Androgen-deprivation therapy in prostate cancer and cardiovascular risk: A science advisory from the American Heart Association, American Cancer Society and American Urological Association endorsed by the American Society for Radiation Oncology","volume":"121","author":"Levin","year":"2010","journal-title":"Circulation"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Fradin, J., Kim, F.J., Storozynsky, E., and Kelly, W.K. (2023). Review of cardiovascular risk of androgen deprivation therapy and the influence of race in men with prostate cancer. Cancer, 15.","DOI":"10.3390\/cancers15082316"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s00345-024-04852-2","article-title":"Cardiovascular disease risk assessment and multidisciplinary care in prostate cancer treatment with ADT: Recommendations from the APMA PCCV expert network","volume":"42","author":"Merseburger","year":"2024","journal-title":"World J. Urol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Li, J.R., Wang, S.S., Chen, C.S., Cheng, C.L., Hung, S.C., Lin, C.H., and Chiu, K.Y. (2022). Conventional androgen deprivation therapy is associated with an increased risk of cardiovascular disease in advanced prostate cancer, a nationwide population-based study. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0270292"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/ijc.34058","article-title":"Association between medical androgen deprivation therapy and long-term cardiovascular disease and all-cause mortality in nonmetastatic prostate cancer","volume":"151","author":"Forster","year":"2022","journal-title":"Int. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/jamaoncol.2024.1549","article-title":"Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis","volume":"10","author":"Taktak","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/JU.0000000000000714","article-title":"Cardiovascular risk in men with prostate cancer: Insights from the RADICAL PC Study","volume":"203","author":"Leong","year":"2020","journal-title":"J. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1161\/ATVBAHA.119.313046","article-title":"Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses","volume":"40","author":"Hu","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/ijc.34557","article-title":"Long-term prognostic impact of cardiovascular comorbidities in patients with prostate cancer receiving androgen deprivation therapy: A population-based competing risk analysis","volume":"153","author":"Chan","year":"2023","journal-title":"Int. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/UPJ.0000000000000487","article-title":"Incidence of Cardiovascular Events in Patients with Prostate Cancer and Treated with Androgen Deprivation Therapy","volume":"11","author":"Lowentritt","year":"2024","journal-title":"Urol. Pract."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s00345-014-1439-6","article-title":"Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: A systematic review and meta-analysis","volume":"33","author":"Carneiro","year":"2015","journal-title":"World J. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.euf.2024.01.008","article-title":"Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG\/RTOG 9202","volume":"10","author":"Mak","year":"2024","journal-title":"Eur. Urol. Focus"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1097\/JU.0000000000000384","article-title":"Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease","volume":"202","author":"Margel","year":"2019","journal-title":"J. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1097\/CM9.0000000000003087","article-title":"Prevalence and risk evaluation of cardiovascular disease in the newly diagnosed prostate cancer population in China: A nationwide, multi-center, population-based cross-sectional study","volume":"137","author":"Zhang","year":"2024","journal-title":"Chin. Med. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jaccao.2020.09.004","article-title":"Duration of Androgen Deprivation Therapy and Cardiovascular Fitness: Delivering the Right Patient the Right Therapy at the Right Time","volume":"2","author":"Narayan","year":"2020","journal-title":"JACC CardioOncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/pcan.2015.45","article-title":"Metabolic abnormalities linked to an increased cardiovascular risk are associated with high-grade prostate cancer: A single biopsy cohort analysis","volume":"19","author":"Truscelli","year":"2016","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.3332\/ecancer.2022.1445","article-title":"Cardiac risk factors and events in patients with prostate cancer commencing androgen deprivation therapy: Analysis from a tertiary care centre in the Middle East","volume":"16","author":"Hassan","year":"2022","journal-title":"Ecancermedicalscience"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaccao.2022.09.008","article-title":"The Burden of Uncontrolled Cardiovascular Risk Factors in Men with Prostate Cancer: A RADICAL-PC Analysis","volume":"5","author":"Klimis","year":"2023","journal-title":"JACC CardioOncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11864-021-00846-z","article-title":"Cardiovascular toxicities of androgen deprivation therapy","volume":"22","author":"Challa","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_42","first-page":"96","article-title":"Effects of androgen deprivation therapy on metabolic markers and bioelectrical impedance analyze in prostate cancer patients","volume":"20","author":"Can","year":"2022","journal-title":"Rev. Int. Androl."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/bjc.2017.280","article-title":"Cardiovascular disease risk and androgen deprivation therapy in patients with localized prostate cancer: A prospective cohort study","volume":"117","author":"Haque","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.2217\/fon-2016-0061","article-title":"Metabolic syndrome in prostate cancer: Impact on risk and outcomes","volume":"12","author":"Karzai","year":"2016","journal-title":"Future Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2006.05.9741","article-title":"Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy","volume":"24","author":"Dobs","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2164\/jandrol.108.005751","article-title":"The dark side of testosterone deficiency: Type II diabetes and insulin resistance","volume":"30","author":"Traish","year":"2009","journal-title":"J. Androl."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1017\/S0954422417000087","article-title":"Current and future strategies for the nutritional management of cardiometabolic complications of androgen deprivation therapy for prostate cancer","volume":"30","author":"Turner","year":"2017","journal-title":"Nutr. Res. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Korczak, J., Mardas, M., Litwiniuk, M., Bogda\u0144ski, P., and Stelmach-Mardas, M. (2023). Androgen Deprivation Therapy for Prostate Cancer Influences Body Composition Increasing Risk of Sarcopenia. Nutrients, 15.","DOI":"10.3390\/nu15071631"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Braga-Basaria, M., Travison, T.G., Taplin, M.E., Lin, A., Dufour, A.B., Habtemariam, D., Nguyen, P.L., Kibel, A.S., Ravi, P., and Bearup, R. (2023). Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0281508"},{"key":"ref_50","first-page":"3671","article-title":"Insulin resistance during androgen deprivation therapy in men with prostate cancer","volume":"130","author":"Basaria","year":"2024","journal-title":"Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/js.2018-00039","article-title":"Androgen deprivation therapy is associated with prolongation of QTc interval in men with prostate cancer","volume":"2","author":"Travison","year":"2018","journal-title":"J. Endocr. Soc."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"163","DOI":"10.6004\/jnccn.2022.7083","article-title":"Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients with Prostate Cancer Based on Existence of Cardiovascular Risk","volume":"21","author":"Dragomir","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Mao, C., Ding, Y., and Xu, N. (2021). A Double-Edged Sword Role of Cytokines in Prostate Cancer Immunotherapy. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.688489"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/ATVBAHA.123.319426","article-title":"FSH Is Responsible for Androgen Deprivation Therapy-Associated Atherosclerosis in Mice by Exaggerating Endothelial Inflammation and Monocyte Adhesion","volume":"44","author":"Wang","year":"2024","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_55","first-page":"187","article-title":"Are GnRH and FSH potentially damaging factors in the cardiovascular system?","volume":"73","author":"Poljak","year":"2018","journal-title":"Pharmazie"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"\u00c1lvarez-Maestro, M., Eguibar, A., Chanca, P., Klett-Mingo, M., G\u00f3mez Rivas, J., Bu\u00f1o-Soto, A., de Bethencourt, F.R., and Ferrer, M. (2021). Androgen Deprivation Therapy in Patients with Prostate Cancer Increases Serum Levels of Thromboxane A2: Cardiovascular Implications. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.653126"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/aja.aja_22_20","article-title":"Androgen deprivation therapy and side effects: Are GnRH antagonists safer?","volume":"23","author":"Freedland","year":"2021","journal-title":"Asian J Androl."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/21681805.2018.1522372","article-title":"FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist","volume":"52","author":"Crawford","year":"2018","journal-title":"Scand. J. Urol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jacbts.2023.10.010","article-title":"Follicle-Stimulating Hormone Exacerbates Cardiovascular Disease in the Presence of Low or Castrate Testosterone Levels","volume":"9","author":"Duivenvoorden","year":"2023","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4049\/jimmunol.2200475","article-title":"Follicle-Stimulating Hormone Provokes Macrophages to Secrete IL-1\u03b2 Contributing to Atherosclerosis Progression","volume":"210","author":"Han","year":"2023","journal-title":"J. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.urolonc.2017.01.025","article-title":"The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy","volume":"35","author":"Crawford","year":"2017","journal-title":"Urol. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/1756287215617872","article-title":"Androgen deprivation therapy and cardiovascular disease: What is the linking mechanism?","volume":"8","author":"Zareba","year":"2016","journal-title":"Ther. Adv. Urol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3389\/fendo.2019.00136","article-title":"FSH Beyond Fertility","volume":"10","author":"Lizneva","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1159\/000527239","article-title":"Follicle-Stimulating Hormone Accelerates Atherosclerosis by Activating PI3K\/Akt\/NF-\u03baB Pathway in Mice with Androgen Deprivation","volume":"59","author":"Piao","year":"2022","journal-title":"J. Vasc. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.21037\/tau-23-114","article-title":"Are higher follicle-stimulating hormone levels before androgen deprivation therapy for prostate cancer associated with oncological and cardiac outcomes and overall survival?\u2014A population-level analysis","volume":"12","author":"Dymanus","year":"2023","journal-title":"Transl. Androl. Urol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/cvr\/cvz020","article-title":"Cardiac arrhythmia considerations of hormone cancer therapies","volume":"115","author":"Barber","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e017267","DOI":"10.1161\/JAHA.120.017267","article-title":"Impact of Medical Castration on Malignant Arrhythmias in Patients with Prostate Cancer","volume":"10","author":"Hasegawa","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41391-022-00555-0","article-title":"Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: An observational study in Taiwan","volume":"26","author":"Shao","year":"2023","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Gu, L., Li, X., and Liu, W. (2023). Adverse cardiovascular effect following gonadotropin-releasing hormone antagonist versus GnRH agonist for prostate cancer treatment: A systematic review and meta-analysis. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1157857"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.eururo.2020.06.002","article-title":"Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials","volume":"79","author":"Abufaraj","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2147\/TCRM.S249208","article-title":"Cardiovascular risk profile in prostate cancer patients treated with GnRH agonists versus antagonists: An Italian real world analysis","volume":"16","author":"Perrone","year":"2020","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","article-title":"Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist","volume":"65","author":"Albertsen","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/bju.15059","article-title":"Lower odds of cardiac events for gonadotrophin-releasing hormone antagonists versus agonists","volume":"126","author":"Cone","year":"2020","journal-title":"BJU Int."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1007\/s00120-021-01583-9","article-title":"Kardiovaskul\u00e4re Komplikationen unter Androgenentzugstherapie: Vorteil f\u00fcr Gonadotropin-Releasing-Hormon-Antagonisten? Ein Update [Cardiovascular side effects in patients undergoing androgen deprivation therapy: Superiority of gonadotropin-releasing hormone antagonists? An update]","volume":"60","author":"Thiele","year":"2021","journal-title":"Urologe. A"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1001\/jamaoncol.2023.7279","article-title":"Efficacy and Safety of Radiotherapy Plus Relugolix in Men with Localized or Advanced Prostate Cancer","volume":"10","author":"Spratt","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_76","first-page":"22","article-title":"First Oral Hormone for Treating Prostate Cancer","volume":"121","author":"Aschenbrenner","year":"2021","journal-title":"Am. J. Nurs."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2125.2010.03660.x","article-title":"Drug- and non-drug-associated QT interval prolongation","volume":"70","author":"Eijgelsheim","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Tsuji, Y., Yamazaki, M., Shimojo, M., Yanagisawa, S., Inden, Y., and Murohara, T. (2024). Mechanisms of torsades de pointes: An update. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1363848"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/cpdd.112","article-title":"Evaluation of the pharmacokinetics and pharmacodynamics of two leuprolide acetate 45\u2009mg 6-month depot formulations in patients with prostate cancer","volume":"3","author":"Mostafa","year":"2014","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_81","first-page":"63","article-title":"Effectiveness of Subcutaneously Administered Leuprolide Acetate to Achieve Low Nadir Testosterone in Prostate Cancer Patients","volume":"20","author":"Pieczonka","year":"2018","journal-title":"Rev. Urol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.euo.2023.11.024","article-title":"Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study","volume":"7","author":"Tutrone","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.eururo.2023.09.007","article-title":"Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study","volume":"84","author":"Tombal","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.eururo.2022.08.029","article-title":"Relugolix: Five Reasons Why the US Food and Drug Administration Should Have Exercised Restraint","volume":"83","author":"Powell","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.2217\/fon-2021-0575","article-title":"Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer","volume":"17","author":"George","year":"2021","journal-title":"Future Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Saad, F., George, D.J., Cookson, M.S., Saltzstein, D.R., Tutrone, R., Bossi, A., Brown, B., Selby, B., Lu, S., and Tombal, B. (2023). Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer. Cancers, 15.","DOI":"10.3390\/cancers15194854"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1210\/jc.2015-2770","article-title":"Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males","volume":"100","author":"MacLean","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40265-014-0211-y","article-title":"Degarelix: A review of its use in patients with prostate cancer","volume":"74","author":"Carter","year":"2014","journal-title":"Drugs"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.euo.2021.07.002","article-title":"The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials","volume":"5","author":"Abufaraj","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"ref_90","first-page":"39","article-title":"Evaluation of degarelix in the management of prostate cancer","volume":"2","year":"2010","journal-title":"Cancer Manag. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.121.056810","article-title":"Cardiovascular Safety of Degarelix Versus Leuprolide in Patients with Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial","volume":"144","author":"Lopes","year":"2021","journal-title":"Circulation"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s40261-017-0547-7","article-title":"Effect of Degarelix, a Gonadotropin-Releasing Hormone Receptor Antagonist for the Treatment of Prostate Cancer, on Cardiac Repolarisation in a Randomised, Placebo and Active Comparator Controlled Thorough QT\/QTc Trial in Healthy Men","volume":"37","author":"Olsson","year":"2017","journal-title":"Clin. Drug Investig."},{"key":"ref_93","first-page":"e9041","article-title":"Shock From Twisting Peaks: A Rare Case of Recurrent Torsades de Pointes Secondary to Leuprolide-Induced Prolonged QT","volume":"12","author":"Abbasi","year":"2020","journal-title":"Cureus"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1080\/14656566.2021.1948012","article-title":"Current and emerging gonadotropin-releasing hormone (GnRH) antagonists for the treatment of prostate cancer","volume":"22","author":"Moussa","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.21873\/anticanres.16311","article-title":"Comparison of Quality of Life and Injection Site Reactions after Switching from Degarelix 80 mg to 480 mg in Advanced Prostate Cancer: A Prospective Trial","volume":"43","author":"Miyajima","year":"2023","journal-title":"Anticancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1758835921998586","DOI":"10.1177\/1758835921998586","article-title":"Relugolix: A novel androgen deprivation therapy for management of patients with advanced prostate cancer","volume":"13","author":"Saad","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/1756287212461048","article-title":"Experience with degarelix in the treatment of prostate cancer","volume":"5","author":"Shore","year":"2013","journal-title":"Ther. Adv. Urol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/andr.13107","article-title":"Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy","volume":"10","author":"Sasaki","year":"2022","journal-title":"Andrology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2147\/PPA.S106629","article-title":"Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: A review of the literature","volume":"10","author":"Eek","year":"2016","journal-title":"Patient Prefer. Adherence"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/pcan.2011.55","article-title":"Cause-specific mortality following radical prostatectomy","volume":"15","author":"Shikanov","year":"2011","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1200\/JCO.2007.14.6217","article-title":"Cancer survivors\u2019 adherence to lifestyle behavior recommendations and associations with health-related quality of life: Results from the American Cancer Society\u2019s SCS-II","volume":"26","author":"Blanchard","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e210070","DOI":"10.1001\/jamanetworkopen.2021.0070","article-title":"Assessment and Management of Cardiovascular Risk Factors Among US Veterans with Prostate Cancer","volume":"4","author":"Sun","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Poon, D.M.C., Tan, G.M., Chan, K., Chan, M.T.Y., Chan, T.W., Kan, R.W.M., Lam, M.H.C., Leung, C.L.H., Wong, K.C.W., and Kam, K.K.H. (2024). Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: Consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1345322"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Rog\u00e9, M., Guimas, V., Rio, E., Vaugier, L., Perennec, T., Alexandre, J., Supiot, S., and Martin Mervoyer, E. (2023). Cardiologist-Performed Baseline Evaluation with an Assessment of Coronary Status for Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: Impact on Newly Diagnosed Coronary Artery Disease. Cancers, 15.","DOI":"10.3390\/cancers15164157"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"212","DOI":"10.5489\/cuaj.8687","article-title":"Screening and management of metabolic, cardiac, and bone health in prostate cancer patients on androgen deprivation therapy A survey of specialized physicians","volume":"18","author":"Nguyen","year":"2024","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","article-title":"Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer","volume":"133","author":"Bhatia","year":"2016","journal-title":"Circulation"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/eurheartj\/ehn018","article-title":"Risk factors for myocardial infarction in women and men: Insights from the INTERHEART study","volume":"29","author":"Anand","year":"2008","journal-title":"Eur. Heart J."},{"key":"ref_108","first-page":"j2099","article-title":"Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: Prospective cohort study","volume":"357","author":"Coupland","year":"2017","journal-title":"BMJ"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2976811","DOI":"10.1155\/2022\/2976811","article-title":"Assessment and Mitigation of Cardiovascular Risk for Prostate Cancer Patients: A Review of the Evidence","volume":"2022","author":"Davey","year":"2022","journal-title":"Int. J. Clin. Pract."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3390\/tomography8020050","article-title":"Assessment of Aortoiliac Atherosclerotic Plaque on CT in Prostate Cancer Patients Undergoing Treatment","volume":"8","author":"Lee","year":"2022","journal-title":"Tomography"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"102107","DOI":"10.1016\/j.clgc.2024.102107","article-title":"Coronary Microvascular Dysfunction in Men with Prostate Cancer Receiving Androgen-Deprivation Therapy","volume":"22","author":"Welch","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"E458","DOI":"10.5489\/cuaj.6685","article-title":"Optimizing screening and management of cardiovascular health in prostate cancer: A review","volume":"14","author":"Kenk","year":"2020","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1161\/CIR.0000000000000534","article-title":"Cardiovascular health in African Americans: A scientific statement from the American Heart Association","volume":"136","author":"Carnethon","year":"2017","journal-title":"Circulation"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1200\/JCO.23.00949","article-title":"Disparities with Systemic Therapies for Black Men Having Advanced Prostate Cancer: Where Do We Stand?","volume":"42","author":"Gong","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e2415911","DOI":"10.1001\/jamanetworkopen.2024.15911","article-title":"Androgen Deprivation Therapy and Outcomes After Radiation Therapy in Black Patients with Prostate Cancer","volume":"7","author":"Morgan","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jpainsymman.2009.09.013","article-title":"Trends and racial differences in the use of androgen deprivation therapy for metastatic prostate cancer","volume":"39","author":"Carson","year":"2010","journal-title":"J. Pain Symptom Manag."},{"key":"ref_117","first-page":"246","article-title":"Race and Time to Receipt of Androgen Deprivation Therapy Among Men with Metastatic Prostate Cancer","volume":"111","author":"Cobran","year":"2019","journal-title":"J. Natl. Med. Assoc."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1001\/jamaoncol.2019.0826","article-title":"Association of Black Race with Prostate Cancer-Specific and Other-Cause Mortality","volume":"5","author":"Dess","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/cncr.32666","article-title":"Survival of African American and non-Hispanic white men with prostate cancer in an equal-access health care system","volume":"126","author":"Riviere","year":"2020","journal-title":"Cancer"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/oncolo\/oyab057","article-title":"Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer","volume":"27","author":"Freeman","year":"2022","journal-title":"Oncologist"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ijrobp.2017.02.020","article-title":"National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer","volume":"98","author":"Yang","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1161\/CIRCULATIONAHA.114.008820","article-title":"ABCDE steps to prevent heart disease in breast cancer survivors","volume":"130","author":"Montazeri","year":"2014","journal-title":"Circulation"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11936-024-01035-5","article-title":"Understanding Cardiovascular Risk in Prostate Cancer: Role of Disparities, Diabetes, and Aging","volume":"26","author":"Nain","year":"2024","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jaccao.2021.09.014","article-title":"How to Treat Prostate Cancer with Androgen Deprivation and Minimize Cardiovascular Risk: A Therapeutic Tightrope","volume":"3","author":"Narayan","year":"2021","journal-title":"JACC CardioOncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s11886-023-01909-3","article-title":"Approaches to Prevent and Manage Cardiovascular Disease in Patients Receiving Therapy for Prostate Cancer","volume":"25","author":"Ng","year":"2023","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_126","first-page":"33","article-title":"Cardiometabolic healthcare for men with prostate cancer: An MD Anderson Cancer Center experience","volume":"9","author":"Hahn","year":"2023","journal-title":"Cardiooncology"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1007\/s12325-023-02634-7","article-title":"Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer","volume":"40","author":"Shore","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11936-020-00873-3","article-title":"Cardiovascular Complications of Prostate Cancer Therapy","volume":"22","author":"Campbell","year":"2020","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1016\/j.jacc.2019.02.079","article-title":"Rivaroxaban plus aspirin versus aspirin in relation to vascular risk in the COMPASS trial","volume":"73","author":"Anand","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e01","DOI":"10.15420\/ecr.2023.40","article-title":"Dual-pathway Inhibition with Low-dose Aspirin and Rivaroxaban versus Aspirin Monotherapy in Patients with Coronary Artery Disease and Peripheral Artery Disease: Systematic Literature Review and Meta-analysis","volume":"19","author":"Sibbing","year":"2023","journal-title":"Eur. Cardiol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/1744666X.2018.1440206","article-title":"Statin-induced myalgia and myositis: An update on pathogenesis and clinical recommendations","volume":"14","author":"Milisenda","year":"2018","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_132","first-page":"e68316","article-title":"Effectiveness of Coenzyme Q10 Supplementation in Statin-Induced Myopathy: A Systematic Review","volume":"16","author":"Ahmad","year":"2024","journal-title":"Cureus"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41569-018-0098-5","article-title":"Safety and efficacy of statin therapy","volume":"15","author":"Adhyaru","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Rikhi, R., and Shapiro, M.D. (Curr. Cardiol. Rep., 2024). Impact of Statin Therapy on Diabetes Incidence: Implications for Primary Prevention, Curr. Cardiol. Rep., in press.","DOI":"10.1007\/s11886-024-02141-3"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.recesp.2019.02.023","article-title":"Beta-blockers: Historical Perspective and Mechanisms of Action","volume":"72","author":"Oliver","year":"2019","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Johner, N., Gencer, B., and Roffi, M. (2024). Routine beta-blocker therapy after acute coronary syndromes: The end of an era?. Eur. J. Clin. Investig.","DOI":"10.1111\/eci.14309"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10557-016-6652-7","article-title":"Efficacy of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in coronary artery disease without heart failure in the modern statin era: A meta-analysis of randomized-controlled trials","volume":"30","author":"Hoang","year":"2016","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1751-7176.2011.00508.x","article-title":"Angiotensin-converting enzyme inhibitors","volume":"13","author":"Izzo","year":"2011","journal-title":"J. Clin. Hypertens."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11906-018-0859-x","article-title":"ACE Inhibitor-Induced Angioedema: A Review","volume":"20","author":"Kostis","year":"2018","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Preston, M.A., Ebrahimi, R., Hong, A., Bobbili, P., Desai, R., Duh, M.S., Gandhi, R., Hanson, S., Dufour, R., and Morgans, A.K. (Urol. Oncol., 2024). Risk of cardiovascular events following intermittent and continuous androgen deprivation therapy in patients with nonmetastatic prostate cancer, Urol. Oncol., in press.","DOI":"10.1016\/j.urolonc.2024.05.026"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/jamaoncol.2024.0860","article-title":"Cardiovascular Risk in Prostate Cancer-A Call to Action?","volume":"10","author":"Atkins","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41391-022-00640-4","article-title":"Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: Analysis of real-life data from Eudra-Vigilance and Food and Drug Administration databases entries","volume":"26","author":"Cicione","year":"2023","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00345-016-1818-2","article-title":"The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK","volume":"34","author":"Rosario","year":"2016","journal-title":"World J. Urol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2340\/1651-226X.2024.20337","article-title":"Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide","volume":"63","author":"Baser","year":"2024","journal-title":"Acta Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/pros.24244","article-title":"Endothelial dysfunction after androgen deprivation therapy and the possible underlying mechanisms","volume":"82","author":"Teoh","year":"2022","journal-title":"Prostate"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"MacLean, C.M., Ulys, A., Jankevi\u010dius, F., Salad\u017einskas, \u017d., van Os, S., and Larsen, F. (2023). Safety, Pharmacokinetic and Pharmacodynamic Evaluation of Teverelix for the Treatment of Hormone-Sensitive Advanced Prostate Cancer: Phase 2 Loading-Dose-Finding Studies. Medicina, 59.","DOI":"10.3390\/medicina59040681"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/cpdd.1415","article-title":"A Model-Informed Drug Development Approach to Design a Phase 3 Trial of Teverelix Drug Product in Advanced Prostate Cancer Patients with Increased Cardiovascular Risk","volume":"13","author":"Sannala","year":"2024","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s11255-018-1854-5","article-title":"Estrogen therapy in patients with prostate cancer: A contemporary systematic review","volume":"50","author":"Reis","year":"2018","journal-title":"Int. Urol. Nephrol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.clon.2023.10.054","article-title":"A Repurposing Programme Evaluating Transdermal Oestradiol Patches for the Treatment of Prostate Cancer within the PATCH and STAMPEDE Trials: Current Results and Adapting Trial Design","volume":"36","author":"Gilbert","year":"2024","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(21)00100-8","article-title":"Transdermal oestradiol for androgen suppression in prostate cancer: Long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme","volume":"397","author":"Langley","year":"2021","journal-title":"Lancet"},{"key":"ref_153","first-page":"e220182","article-title":"Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: A narrative review","volume":"11","author":"Krijgh","year":"2022","journal-title":"Endocr. Connect."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/11\/1727\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:17:43Z","timestamp":1760113063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/11\/1727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":153,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["medicina60111727"],"URL":"https:\/\/doi.org\/10.3390\/medicina60111727","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,22]]}}}